May 17th 2024
Leaders in the space discuss aspects of experimental drug support and more at this year’s US Pharma and Biotech Summit.
Getting Value From End-of-Life-Cycle Pharmaceuticals
A review of 84 branded pharmaceutical products with changed ownership as of 2005 shows that many of them can continue to sell, often with much higher prices By Albert I. Wertheimer, PhD, MBA, Temple University, and Ellen F. Loh, BS, MBA, University of Maryland, Baltimore